NLRP3 and metabolic syndrome: Aberrant activation of the NLRP3 inflammasome is linked to various diseases, including diabetes, atherosclerosis, metabolic syndrome, and cardiovascular and neurodegenerative diseases, raising tremendous clinical interest in exploring the potential beneficial/therapeutic effect of NLRP3 inflammasome inhibitors.